ABOUT GlobeImmune NEWSROOM CAREERS CONTACT US INVESTORS PLATFORM CANCER INFECTIOUS DISEASE GlobeImmune | Cancer | GI-6301 / Brachyury GI-6301 / Brachyury Print The GI-6301 Tarmogen is designed to target cancers expressing the brachyury protein, which plays a role in metastatic progression of certain cancers and the initiation of chordoma. GI-6301 has been exclusively licensed to Celgene. A variety of cancers express the brachyury protein, including lung, breast, colon, bladder, kidney, ovary, uterus and prostate. Brachyury is also expressed in all chordomas, a rare and difficult-to-treat bone tumor. The frequency of brachyury expression increases with stage of disease. In lung cancer, approximately 60% of later stage lung cancer biopsies showed expression of brachyury, compared to approximately 40% of earlier stage lung cancers. In July 2013, Celgene exercised its option to obtain an exclusive license to the GI-6300 program, including GI-6301. We anticipate that GI-6301 will be investigated in chordoma, and other brachyury-expressing cancers. Clinical Program Phase 1 Study In February 2012, in collaboration with the National Cancer Institute (NCI), we initiated a Phase 1 clinical trial with GI-6301 in subjects with metastatic cancers who have failed previous therapy or have no further therapeutic options. The trial is an open label, single agent, sequential dose escalation trial, with three to six subjects per dose group. Three dose levels were planned under the original protocol: 4YU, 16YU and 40YU. Ten additional subjects were enrolled in an expansion group at the 40YU dose. The protocol was amended in November 2013 to add a fourth, 80YU dose group of ten subjects to the trial. The endpoints of this study are safety, tolerability, brachyury-specific immune responses and clinical benefit. Initial data from this study demonstrates that GI-6301 is generally well tolerated at all dose levels. Cancer Oncology Pipeline GI-6301 / Brachyury GI-6207 / CEA GI-4000 / Mutated Ras SITE MAP » CONTACT US » CURRENT EMPLOYEES / INTRANET » Copyright © GlobeImmune Inc. All Rights Reserved. Corporate Headquarters 1450 Infinite Drive Louisville, Colorado 80027 Phone: 720.667.2300